Databricks did not become valuable because Apache Spark existed. Spark was open source. Anyone could use it. The capability was freely available. Databricks became valuable because it built the platform around Spark — managed deployment, collaborative notebooks, enterprise security, governance, performance optimization, support, and the operational experience that made Spark practical for organizations that could not staff a team of Spark experts. The open-source project established what was possible. The platform made it accessible at scale.

I think Nexplane can follow a similar pattern. The open-source project establishes the core ideas: what a change request looks like, how rollback should be designed, how human review should work, what the execution and verification model should be. It gives practitioners a real tool they can use and inspect. It builds trust and community. It creates an ecosystem of people who understand the approach and have opinions about it. That foundation is what makes a commercial product viable — not because it locks people in, but because the commercial product solves the next tier of real problems that the community version does not address.

What those enterprise problems look like is not mysterious. Large organizations need audit trails that satisfy compliance requirements. They need governance workflows that span teams and approval chains that involve multiple stakeholders. They need managed deployment so they do not have to maintain the platform themselves. They need SLAs and support. They need integrations with enterprise identity systems and ticketing platforms. They need the ability to manage Nexplane at scale across dozens of environments. None of that is available in a self-hosted open-source deployment, and that is fine. The platform around the thing is where the enterprise value lives.

The trick — and this is where the analogy has a real edge to it — is to make the open-source core valuable enough to matter. Databricks worked because Spark was genuinely important technology, not because Databricks marketed it well. If the community version of Nexplane is a stripped-down teaser that only hints at the real capability, the analogy breaks. Practitioners will not adopt it, trust will not accumulate, and there is no foundation for the commercial layer. The open core has to be the real thing. The platform has to solve problems the community version legitimately cannot. That is the distinction that makes the model work.

I am also realistic about the fact that this takes time. Databricks was not an overnight success. Trust in infrastructure tooling accumulates slowly because the stakes are high and practitioners are appropriately skeptical of new platforms that want access to their production systems. That is the right disposition. The open-source path is the patient path. It is also, I think, the only honest path for a product where trust is the entire foundation.